NRG1 and cancer: The prevalence of NRG1 rearrangements in other types of cancers is similar to NSCLC and amounts to 0.5% in cholangiocarcinoma, pancreatic carcinoma, and renal cell carcinoma, 0.4% in ovarian cancer, and 0.2% in breast cancer and sarcoma [7,9,10].